{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T02:41:57Z","timestamp":1772160117831,"version":"3.50.1"},"reference-count":33,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T00:00:00Z","timestamp":1581984000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To determine the safety of a higher starting dose of basal insulin in overweight\/obese patients with type 2 diabetes (T2D).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>\n                      This 16\u2010week, randomized, multicentre, open\u2010label trial enrolled adults with T2D (body mass index 25\u201340\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ) and suboptimal glycaemic control (glycated haemoglobin [HbA1c] 7.5\u201311.0% [58\u201397 mmol\/mol] and fasting plasma glucose [FPG] &gt;9.0\u2009mmol\/L) with two to three oral anti\u2010hyperglycaemic drugs at 51 centres in China. Patients were randomized (1:1) to a higher (0.3\u2009U\/kg) or standard (0.2\u2009U\/kg) starting dose of insulin glargine 100\u2009U\/mL, which was then titrated to achieve a self\u2010monitored fasting blood glucose (FBG) of 4.4 to 5.6\u2009mmol\/L. The primary endpoint was the percentage of patients with \u22651 episode of overall confirmed hypoglycaemia (\u22643.9\u2009mmol\/L or severe).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At the end of study (n = 866), 11.0% patients treated with the 0.3\u2009U\/kg starting insulin dose experienced overall confirmed hypoglycaemia versus 8.6% of patients treated with 0.2\u2009U\/kg (estimated difference 2.1%, 95% confidence interval\u2009\u2212\u20091.68, 5.89). The proportions of patients with symptomatic (9.8% vs 7.0%;\n                      <jats:italic>P<\/jats:italic>\n                      = 0.128) and nocturnal hypoglycaemia (2.7% vs 1.2%;\n                      <jats:italic>P<\/jats:italic>\n                      = 0.102) were similar in the two groups. There were no events of severe hypoglycaemia or FBG &lt;3.0\u2009mmol\/L during the 16\u2010week treatment, and achievement of HbA1c &lt;7.0% (53 mmol\/mol) (37.1% vs 37.1%) or FPG &lt;5.6\u2009mmol\/L (15.9% vs 16.3%), &lt;6.1\u2009mmol\/L (27.6% vs 26.1%), or\u2009&lt;\u20097.0\u2009mmol\/L (48.8% vs 48.3%) without hypoglycaemia were comparable in the two groups. Moreover, the mean time was shorter (4.53, 3.95 and 2.74\u2009weeks vs 5.51, 5.21 and 3.64\u2009weeks) and number of titrations was lower (3.5, 3.0 and 2.0 vs 4.3, 4.0 and 2.8) to achieve self\u2010monitored FBG targets of &lt;5.6, &lt;6.1 and\u2009&lt;7.0\u2009mmol\/L in the higher versus the standard insulin dose group (all\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Among overweight\/obese patients with T2D, a higher insulin starting dose was as safe as the standard starting dose, and self\u2010monitored FBG targets were achieved earlier with the higher versus the standard dose.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.13967","type":"journal-article","created":{"date-parts":[[2020,1,16]],"date-time":"2020-01-16T00:29:58Z","timestamp":1579134598000},"page":"838-846","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Higher versus standard starting dose of insulin glargine 100\u2009U\/mL in overweight or obese Chinese patients with type 2 diabetes: Results of a multicentre, open\u2010label, randomized controlled trial (BEYOND VII)"],"prefix":"10.1111","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1305-1598","authenticated-orcid":false,"given":"Linong","family":"Ji","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism Peking University People's Hospital  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hailong","family":"Wan","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Panjin Central Hospital  Panjin China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Binhong","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, People's Hospital of Liaoning Province  Liaoning China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueying","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Jinzhou Central Hospital  Jinzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junfen","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Second Hospital of Shijiazhuang  Shijiazhuang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongwen","family":"Bian","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism Jiangsu Province Institute of Geriatrics  Nanjing Jiangsu China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wuyan","family":"Pang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism Huaihe Hospital of Henan University  Kaifeng Henan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism Central Hospital Affiliated to Shenyang Medical College  Shenyang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Second Hospital of Chaoyang City  Chaoyang City China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Bian","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Cangzhou People's Hospital  Cangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengnan","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism Dalian Municipal Central Hospital Affiliated of Dalian Medical University  Dalian Liaoning China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Condoleon","sequence":"additional","affiliation":[{"name":"Sanofi, Paris  France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Feng","sequence":"additional","affiliation":[{"name":"Sanofi  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Zhang","sequence":"additional","affiliation":[{"name":"Sanofi  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Cui","sequence":"additional","affiliation":[{"name":"Sanofi  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,2,18]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2827"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4729-5"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-0435"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2013.02.035"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0985"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-13-602"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2258"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.2337\/db18-1583-P"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12886"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-019-01383-w"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-015-0100-8"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13064"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2018.0230"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.2337\/db18-1583-P"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.005945"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.4158\/CS-2017-0153"},{"issue":"1","key":"e_1_2_9_18_1","first-page":"4","article-title":"Standards of care for type 2 diabetes in China","volume":"10","author":"Chinese Diabetes Society","year":"2018","journal-title":"Chin J Diabetes Mellitus"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2413"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.12963"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v5.i1.69"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-018-0381-9"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-017-0322-z"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0717-x"},{"key":"e_1_2_9_25_1","unstructured":"European Medicines Agency. Guideline for good clinical practice E6(R2). 2016;https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-e-6-r2-guideline-good-clinical-practice-step-5_en.pdf. Accessed 13 November 2019."},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.7115"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2014.08.003"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13653"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1177\/193229680700100412"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-9025"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2019.0037"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.6.1282"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2016.40.6.423"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(13)70021-4"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.13967","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.13967","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.13967","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T06:41:26Z","timestamp":1761892886000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.13967"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,18]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["10.1111\/dom.13967"],"URL":"https:\/\/doi.org\/10.1111\/dom.13967","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.13967\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13967\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13967\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13967\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13967\/v3\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13967\/v1\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13967\/v1\/review4","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13967\/v1\/review5","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13967\/v1\/review6","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13967\/v1\/review7","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13967\/v1\/review8","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13967\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13967\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13967\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13967\/v3\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13967\/v3\/response1","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,18]]},"assertion":[{"value":"2019-10-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}